Improvement and innovations applied to the detection and monitoring of immunopathologies and cancer

• Grant number: 17/10089-0
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Start date: March 01, 2018
• End date: February 29, 2020
• Field of knowledge: Health Sciences - Medicine - Maternal and Child Health
• Agreement: FINEP - PIPE/PAPPE Grant
• Principal Investigator: Edgar Borges de Oliveira Junior
• Grantee: Edgar Borges de Oliveira Junior
• Company: Immunogenic Assessoria e Diagnóstico em Saúde Ltda - EPP
• CNAE: Pesquisa e desenvolvimento experimental em ciências físicas e naturais ; Atividades de apoio à gestão de saúde
• City: São Paulo
• Associated research grant: 16/00595-2 - Improvement and innovation applied to the test newborn screening for congenital immunodeficiencies, AP.PIPE
• Associated research grant(s): 22/01693-9 - Development of a commercial kit for neonatal screening of primary immunodeficiencies, AP.PIPE
• Associated scholarship(s): 18/26666-9 - Improvement and innovations applied to the detection and monitoring of immunopathologies and cancer, BP.TT; 18/00314-9 - Improvement and innovations applied to the detection and monitoring of Immunopathologies and Cancer, BP.TT; 18/00289-4 - Improvement and innovations applied to the detection and monitoring of immunopathologies and Cancer, BP.PIPE

Abstract

Primary immunodeficiencies (PIDs) are a group of diseases with heterogeneous expression, which usually manifest from the first days of life to seven years of age. The objective of neonatal screening is to identify asymptomatic newborns with potentially serious or fatal diseases with the possibility of treatment, resulting in a significant reduction of morbidity and mortality. The Kappa / Lambda balance, we identified other possibilities of using LEC reading associated with the reading of KRECs, as an improvement in the accuracy of B lymphocytes analysis, allowing the identification of congenital immunodeficiencies that present partial reduction of B lymphocytes. Another application to be validated is an evaluation of KRECs and LECs in patients with chronic lymphocytic leukemia and multiple miloma, which we believe may be possible to identify them in asymptomatic phases of the disease. Our goal is to develop a new tool for the early identification of all forms of agamopathies in all their forms in newborns, in addition to possible associated syndromes, as well as some types of cancers such as Chronic Lymphoid Leukemia and Multiple Myeloma in adults, another extreme of human life. Once the test has been validated, we will have at the end of this project a final product in the form of a kit (plasmids + oligos + probe) that will allow us to patent and sell, as well as the possibility of offering screening services to these physicians, helping them with diagnosis and Decisions on the appropriate treatment for each case. We intend to be a reference in Brazil in screening and diagnosis for serious immunopathologies and some types of cancers, and can expand the market abroad, starting with Latin America and a second stage Europe. (AU)